Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 71 clinical trials
None
Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas

A Phase II Study of Hypofractionated Stereotactic Radiotherapy (HSRT) With Anlotinib in Patients With Recurrent High-Grade Glioma. The primary endpoint is overall survival after radiotherapy

karnofsky performance status
chemoradiotherapy
measurable disease
initial diagnosis
recurrent malignant glioma
  • 1 views
  • 23 Jan, 2021
  • 1 location
None
Fimepinostat in Treating Brain Tumors in Children and Young Adults

This trial studies how well fimepinostat works in treating patients with newly diagnosed diffuse intrinsic pontine glioma, or medulloblastoma, or high-grade glioma that have come back. Fimepinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

medulloblastoma
monoclonal antibodies
therapeutic conventional surgery
malignant glioma
corticosteroids
  • 3 views
  • 13 Aug, 2021
  • 19 locations
None
REGN2810 in Pediatric Patients With Relapsed Refractory Solid or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Phase 1: To confirm the safety and anticipated recommended phase 2 dose (RP2D) of REGN2810 (cemiplimab) for children with recurrent or refractory solid or Central Nervous System (CNS) tumors To characterize the pharmacokinetics (PK) of REGN2810 given in children with recurrent or refractory solid or CNS tumors Phase 2 (Efficacy …

karnofsky performance status
central nervous system tumor
re-irradiation
cns neoplasm
regn2810
  • 24 views
  • 09 Jun, 2021
  • 18 locations
None
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MPP2+ Recurrent or Progressive Glioblastoma

This phase I trial studies the side effects and best dose of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain in treating patients with MPP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive). Vaccines made from a gene-modified virus may …

immunohistochemistry
karnofsky performance status
serum pregnancy test
tumor cells
mpp2
  • 1 views
  • 26 Jun, 2021
  • 1 location
None
TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma RCT

the treatment of recurrent malignant gliomas. AVAglioRTOG 0825 subgroup analysis showed that TMZ combined with antiangiogenic drugs may have advantages in the first-line treatment of patients with

brain tumor
bevacizumab
recurrent glioma
blood transfusion
temozolomide
  • 8 views
  • 22 Jan, 2021
  • 1 location
None
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma

This phase I trial studies the side effects and best dose of memory-enriched T cells in treating patients with grade II-IV glioma that has come back (recurrent) or does not respond to treatment (refractory). Memory enriched T cells such as HER2(EQ)BB/CD19t+ T cells may enter and express its genes in …

karnofsky performance status
seizure
malignant glioma
dexamethasone
measurable disease
  • 100 views
  • 22 Aug, 2021
  • 3 locations
None
A Study of PRT811 in Participants With Advanced Solid Tumors CNS Lymphoma and Gliomas

This is a Phase 1 dose-escalation study of PRT811, a protein arginine N-methyltransferase (PRMT) 5 inhibitor, in subjects with advanced cancers and high-grade gliomas who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of …

solid tumour
cancer
  • 7 views
  • 11 Nov, 2021
  • 8 locations
None
The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation

evaluate whether evolocumab crosses the blood brain barrier (BBB) and is measurable in the resected tumor specimens of patients with primary and recurrent high grade glioma or glioblastoma.

malignant glioma
neutrophil count
renal function
  • 0 views
  • 17 Nov, 2021
  • 1 location
None
Safety Study of Pritumumab in Brain Cancer

the recommended Phase 2 dose (RP2D) of escalating, intravenously (IV) administered Pritumumab doses in patients with recurrent gliomas or with brain metastases. Secondary Objectives

  • 0 views
  • 09 Sep, 2021
  • 1 location
None
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

the investigators seek to test the hypothesis that repeated dosing of intraarterial Bevacizumab is safe and effective in the treatment of recurrent malignant glioma. By achieving the aims of this

karnofsky performance status
mixed oligoastrocytoma
MRI
malignant glioma
primary brain neoplasm
  • 96 views
  • 05 Nov, 2021
  • 1 location